The global prothrombin complex concentrates market is expected to be valued at US$ 772.0 million in 2023 and reach a valuation of US$ 1.2 billion by 2033. The demand for prothrombin complex concentrates is estimated to record a steady CAGR of 4.1%, with the United Kingdom, the United States., China, and India emerging as key producers.
In the prothrombin complex concentrates market, there is a growing focus on improving patient safety, with many companies aiming to create safer and more efficient products that have fewer side effects. This trend has resulted in the development of novel prothrombin complex concentrates products such as non-activated prothrombin complex concentrates and recombinant factor VIII products, which have proven to be more effective.
Personalized medicine is a growing trend in the prothrombin complex concentrates market, and companies are developing tailored products to address individual patient needs. This includes products made specifically for patients with different bleeding diseases and precision medications that aim to treat particular genetic abnormalities. There is also a trend toward the development of innovative delivery methods for prothrombin complex concentrates, such as subcutaneous and intranasal delivery systems. These methods are preferred because they are more convenient and can enhance patient adherence to treatment.
To increase efficiency in prothrombin complex concentrates production and distribution, many companies are utilizing data analytics and digital technologies, including predictive analytics, to forecast demand, and digital tools to optimize supply chain management.
The potential for blood clots in prothrombin concentrate complex is one of the key factors limiting market growth. Blood clots can cause problems like venous thromboembolism, microvascular thrombosis, Disseminated Intravascular Coagulation (DIC), and myocardial infarction. A market study called "Thromboembolic Events after Vitamin K Antagonist Reversal with 4-Factor Prothrombin Complex Concentrate" found that 7.3% of patients who got 4-factor- prothrombin complex concentrates had thromboembolic events. Also, according to the UPMC System Pharmacy and Therapeutics Committee Formulary Evaluation, 2.9% of Kcentra users experienced thromboembolic events after using the medication. This raises safety concerns about employing factor IX complex goods, which is expected to probably impede the market.
Attributes | Details |
---|---|
Prothrombin Complex Concentrates Market CAGR (2023 to 2033) | 4.1% |
Prothrombin Complex Concentrates Market Size (2023) | US$ 772.0 million |
Prothrombin Complex Concentrates Market Size (2033) | US$ 1.2 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for prothrombin complex concentrates recorded a CAGR of 4.4% between 2018 and 2022, and it's expected to record a CAGR of 4.1% between 2023 and 2033. The market's growth potential could be looked at from short-term, mid-term, and long-term perspectives.
Short Term Outlook (2023 to 2025) | As the global incidence of bleeding disorders continues to rise, there is a growing demand for effective and safe treatments. Prothrombin complex concentrates are becoming increasingly popular due to their ability to quickly reverse the effects of anticoagulant therapy, making them a valuable treatment option for patients with coagulation disorders. |
---|---|
Mid Term Outlook (2025 to 2028 ) | Many companies are investing in research and development to create prothrombin complex concentrates and improve the efficacy and safety of existing products. This investment is expected to lead to the development of new treatments and an expansion of the market. |
Long Term Outlook (2028 to 2032 ) | The increasing availability of healthcare infrastructure in emerging markets such as India and China is creating growth opportunities for prothrombin complex concentrates. The approval of new prothrombin complex concentrates products in these markets can lead to significant growth for manufacturers. |
Using Warfarin to Expand the Market Swiftly
Warfarin has become the most common oral anticoagulant for people with thrombosis. Anti-thrombotic medicine sales, including warfarin, account for around 3% of all drug sales globally and are anticipated to increase.
Fresh frozen plasma (FFP) and other therapies like it can't compete with Prothrombin Complex Concentrate.
A transfusion reaction and volume overload can occur when FFP and other therapies are used. Also, FFP is rarely able to bring the INR back to normal. Prothrombin complex concentrate, on the other hand, is an effective way to normalize the INR and reduce the risk of pathogen transmission.
Problems with clotting caused by Prothrombin Complex Concentrate
Blood clots can happen when prothrombin complex concentrate is given, leading to microvascular thrombosis, disseminated intravascular coagulation, and myocardial infarction. Underlying illnesses, excessive dosages of prothrombin complex concentrate, and unbalanced ingredients can all increase the risk of thrombotic problems.
As the requirement for anticoagulation therapy with oral anticoagulants is increasing amongst the geriatric population, the need to reverse anticoagulation in adverse conditions is also increasing. Thus, the growing geriatric population is expected to fuel the growth of the prothrombin complex concentrates market over the forecast period.
The worldwide incidence of hemophilia is not well known; however, it has been estimated that more than 400,000 people have hemophilia. 75% of people with hemophilia have been estimated to receive inadequate treatment or have no access to treatment.
The prothrombin complex concentrates global manufacturers mainly dominate the market. The manufacturers of prothrombin complex concentrates are competing based on the adoption of prothrombin complex concentrates. The growing demand for optimized & sustainable healthcare has created immense growth opportunities for global manufacturers.
Companies such as Shire, Octapharma AG, and CSL Behring GmbH hold approximately 80% revenue share in the global prothrombin complex concentrates market. Also, companies operating in the market are collaborating with retailers and local distributors to increase the penetration of prothrombin complex concentrates.
According to the discussions held with key opinion leaders in the prothrombin complex concentrates market, substantial growth has been witnessed in the China market for prothrombin complex concentrates. Manufacturers operating in the China and APEC markets are estimated to have significant growth opportunities in the prothrombin complex concentrates market over the forecast period.
The United States prothrombin complex concentrates market is one of the significant and most established markets for prothrombin complex concentrates globally, and it continues to experience growth due to various factors.
One significant factor driving growth in the United States prothrombin complex concentrates market is the increasing incidence of bleeding disorders, such as hemophilia and von Willebrand disease. According to the Centers for Disease Control and Prevention (CDC), hemophilia affects approximately 20,000 people in the United States, while von Willebrand disease affects 1% of the United States population. As the incidence of these disorders continues to rise, the demand for prothrombin complex concentrates is also increasing.
The growing use of prothrombin complex concentrates in emergency medicine is another factor boosting market expansion in the United States. Prothrombin complex concentrates products are commonly used in emergencies to treat patients with acute bleeding or coagulation disorders. The availability of prothrombin complex concentrates in emergency departments, and trauma centers across the United States have led to a significant increase in demand for prothrombin complex concentrates.
India has the potential to become a profitable market for prothrombin complex concentrates due to several factors, although challenges need to be addressed to achieve maximum potential. One of the significant factors that make India attractive is its significant population which results in a substantial number of patients with coagulation disorders, including an estimated 450,000 hemophilia patients, which is one of the maximum numbers globally.
The demand for prothrombin complex concentrates is expected to grow as bleeding disorders increase. India's healthcare infrastructure is another appealing factor that has improved due to the Indian government's various initiatives, leading to an increase in healthcare facilities, including specialized treatment centers for bleeding disorders.
Accessibility to prothrombin complex concentrates has improved, creating market growth opportunities. Also, due to the increasing awareness of bleeding disorders among patients and healthcare professionals, diagnosis and treatment rates have increased, creating a significant demand for prothrombin complex concentrates as patients and physicians seek more effective and safer treatment options.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Hospitals, outpatient surgical centers, specialized clinics, and other places make up the different segments of the market. For the next five years, the market's leadership is anticipated to rest with hospitals and the outpatient surgery segment. This results from the COVID-19 pandemic-related increase in the use of prothrombin complex concentrate, government recommendations, and hospital purchases of more plasma products. The specialty clinics segment is likely to grow because some multiple surgeons and clinics are privately owned.
The others segment, which includes urgent care centers, emergency trauma centers, doctors' offices, and so on, is likely to grow because the government and private players are investing more in improving healthcare facilities.
Based on its use, the market is divided into two categories: congenital and acquired coagulation factor deficiency. The most lucrative market in 2019 was for acquired coagulation factor deficiency, and in the coming years, it is anticipated to expand rapidly.
The segment is expected to grow because there are more cases of life-threatening bleeding linked to the use of warfarin, more cases of induced coagulation factor deficiency during surgery, and new products.
According to the Hemophilia Federation of America, there are about 29,000 cases of bleeding in the United States each year that are caused by taking warfarin. This is expected to make this market segment grow rapidly by 2027. The segment is also going to benefit significantly from the growing Kcentra sales brought on by the COVID-19 situation. On the other hand, government initiatives to find novel treatments for bleeding disorders like Hemophilia B are likely to benefit the congenital coagulation factor deficiency segment.
Companies are using various strategies to expand their market share. These include
The market is estimated to acquire US$ 772 million in 2023.
PCC-related thrombotic complications restrain market growth.
Manufacturers operating in China increase significant growth opportunities in the market.
The increasing incidence of bleeding disorders raises the market.
The global market expanded at a CAGR of 4.4% between 2018 and 2022.
1. Executive Summary | Prothrombin Complex Concentrates Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2017 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2023 to 2033 5.3.1. 3-Factor PCC 5.3.2. 4-Factor PCC 5.4. Y-o-Y Growth Trend Analysis By Product Type, 2017 to 2022 5.5. Absolute $ Opportunity Analysis By Product Type, 2023 to 2033 6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Treatment Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2017 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033 6.3.1. Haemorrhagic Episodes in Factor IX Defficiency - Haemiohilia B 6.3.2. Trauma 6.3.3. Life-Threatening Coagulopathy with Acute Bleeding 6.3.4. Warfarin-Associated Acute Life Threatening Bleeding 6.3.5. Non-Warfarin Anticoagulant Reversal with Acute Bleeding 6.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2017 to 2022 6.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End User , 2017 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User , 2023 to 2033 7.3.1. Compound Pharmacies 7.3.2. Hospital Pharmacies 7.3.3. Retail Pharmacies 7.4. Y-o-Y Growth Trend Analysis By End User , 2017 to 2022 7.5. Absolute $ Opportunity Analysis By End User , 2023 to 2033 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. Asia Pacific Excluding Japan 8.3.6. Japan 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Product Type 9.2.3. By Treatment Type 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Product Type 9.3.3. By Treatment Type 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Argentina 10.2.1.4. Rest of Latin America 10.2.2. By Product Type 10.2.3. By Treatment Type 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Product Type 10.3.3. By Treatment Type 10.3.4. By End User 10.4. Key Takeaways 11. Western Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. France 11.2.1.3. Italy 11.2.1.4. Spain 11.2.1.5. United kingdom 11.2.1.6. Benelux 11.2.1.7. Nordics 11.2.1.8. Rest of Western Europe 11.2.2. By Product Type 11.2.3. By Treatment Type 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Product Type 11.3.3. By Treatment Type 11.3.4. By End User 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Rest of Eastern Europe 12.2.2. By Product Type 12.2.3. By Treatment Type 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Product Type 12.3.3. By Treatment Type 12.3.4. By End User 12.4. Key Takeaways 13. Asia Pacific Excluding Japan Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. ASEAN 13.2.1.3. Australia & New Zealand 13.2.1.4. China 13.2.1.5. Rest of Asia Pacific Excluding Japan 13.2.2. By Product Type 13.2.3. By Treatment Type 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Product Type 13.3.3. By Treatment Type 13.3.4. By End User 13.4. Key Takeaways 14. Japan Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.2. By Product Type 14.2.3. By Treatment Type 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Product Type 14.3.3. By Treatment Type 14.3.4. By End User 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. South Africa 15.2.1.2. GCC Countries 15.2.1.3. Rest of Middle East and Africa 15.2.2. By Product Type 15.2.3. By Treatment Type 15.2.4. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Product Type 15.3.3. By Treatment Type 15.3.4. By End User 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Product Type 16.1.2.2. By Treatment Type 16.1.2.3. By End User 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Product Type 16.2.2.2. By Treatment Type 16.2.2.3. By End User 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Product Type 16.3.2.2. By Treatment Type 16.3.2.3. By End User 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Product Type 16.4.2.2. By Treatment Type 16.4.2.3. By End User 16.5. Argentina 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Product Type 16.5.2.2. By Treatment Type 16.5.2.3. By End User 16.6. Germany 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Product Type 16.6.2.2. By Treatment Type 16.6.2.3. By End User 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Product Type 16.7.2.2. By Treatment Type 16.7.2.3. By End User 16.8. Italy 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Product Type 16.8.2.2. By Treatment Type 16.8.2.3. By End User 16.9. Spain 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Product Type 16.9.2.2. By Treatment Type 16.9.2.3. By End User 16.10. United kingdom 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Product Type 16.10.2.2. By Treatment Type 16.10.2.3. By End User 16.11. Benelux 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Product Type 16.11.2.2. By Treatment Type 16.11.2.3. By End User 16.12. Nordics 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Product Type 16.12.2.2. By Treatment Type 16.12.2.3. By End User 16.13. Poland 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Product Type 16.13.2.2. By Treatment Type 16.13.2.3. By End User 16.14. Russia 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Product Type 16.14.2.2. By Treatment Type 16.14.2.3. By End User 16.15. India 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Product Type 16.15.2.2. By Treatment Type 16.15.2.3. By End User 16.16. ASEAN 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Product Type 16.16.2.2. By Treatment Type 16.16.2.3. By End User 16.17. Australia & New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Product Type 16.17.2.2. By Treatment Type 16.17.2.3. By End User 16.18. China 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Product Type 16.18.2.2. By Treatment Type 16.18.2.3. By End User 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Product Type 16.19.2.2. By Treatment Type 16.19.2.3. By End User 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Product Type 16.20.2.2. By Treatment Type 16.20.2.3. By End User 16.21. GCC Countries 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Product Type 16.21.2.2. By Treatment Type 16.21.2.3. By End User 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Product Type 17.3.3. By Treatment Type 17.3.4. By End User 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Shire 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Octapharma AG 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Takeda Pharmaceutical Company Limited 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Sanquin Blood Supply Foundation 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. CSL Behring GmbH 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Kedrion Biopharma Inc. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Grifols, S.A. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports